158 related articles for article (PubMed ID: 33395496)
1. Pancreatic Neuroendocrine Tumor With Humoral Hypercalcemia and High Tumor PD-L1 Score.
Copur MS; Vargas L; Wedel W; Merani S; Cushman-Vokoun A; Drincic A
Oncology (Williston Park); 2020 Dec; 34(12):548-552. PubMed ID: 33395496
[TBL] [Abstract][Full Text] [Related]
2. Humoral hypercalcemia of malignancy caused by parathyroid hormone-related peptide-secreting neuroendocrine tumors. Report of six cases.
Milanesi A; Yu R; Wolin EM
Pancreatology; 2013; 13(3):324-6. PubMed ID: 23719609
[TBL] [Abstract][Full Text] [Related]
3. Malignant hypercalcaemia related to parathyroid hormone-related peptide (PTHrP) secretion from a metastatic pancreatic neuroendocrine tumour (NET).
Symington M; Davies L; Kaltsas G; Weickert MO
BMJ Case Rep; 2017 Mar; 2017():. PubMed ID: 28331027
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers.
Giannetta E; Sesti F; Modica R; Grossrubatscher EM; Guarnotta V; Ragni A; Zanata I; Colao A; Faggiano A
Front Endocrinol (Lausanne); 2021; 12():665698. PubMed ID: 34093441
[TBL] [Abstract][Full Text] [Related]
5. Concurrent primary hyperparathyroidism and humoral hypercalcemia of malignancy in a patient with multiple endocrine neoplasia type 1.
Milanesi A; Yu R; Geller SA; Burton D; Deftos LJ; Wolin EM
Pancreas; 2011 May; 40(4):634-7. PubMed ID: 21483254
[TBL] [Abstract][Full Text] [Related]
6. The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia.
Wang C; Yu J; Fan Y; Ma K; Ning J; Hu Y; Niu W; Dong X; Wu Y; Li E; Dong D
Ann Clin Lab Sci; 2019 Sep; 49(4):448-456. PubMed ID: 31471333
[TBL] [Abstract][Full Text] [Related]
7. Severe hypercalcemia due to metastatic pancreatic neuroendocrine tumor: a case report.
Behdadnia A; Jeddi M
J Med Case Rep; 2023 Sep; 17(1):400. PubMed ID: 37670372
[TBL] [Abstract][Full Text] [Related]
8. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
9. Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor.
Suteau V; Collin A; Menei P; Rodien P; Rousselet MC; Briet C
Cancer Immunol Immunother; 2020 Oct; 69(10):2053-2061. PubMed ID: 32445029
[TBL] [Abstract][Full Text] [Related]
10. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the Neuroendocrine Tumor Immune Microenvironment.
da Silva A; Bowden M; Zhang S; Masugi Y; Thorner AR; Herbert ZT; Zhou CW; Brais L; Chan JA; Hodi FS; Rodig S; Ogino S; Kulke MH
Pancreas; 2018 Oct; 47(9):1123-1129. PubMed ID: 30153220
[TBL] [Abstract][Full Text] [Related]
12. Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor.
Valdes-Socin H; Almanza MR; Fernández-Ladreda MT; Daele DV; Polus M; Chavez M; Beckers A
Arch Endocrinol Metab; 2017; 61(5):506-509. PubMed ID: 28977163
[TBL] [Abstract][Full Text] [Related]
13. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors.
Sampedro-Núñez M; Serrano-Somavilla A; Adrados M; Cameselle-Teijeiro JM; Blanco-Carrera C; Cabezas-Agricola JM; Martínez-Hernández R; Martín-Pérez E; Muñoz de Nova JL; Díaz JÁ; García-Centeno R; Caneiro-Gómez J; Abdulkader I; González-Amaro R; Marazuela M
Sci Rep; 2018 Dec; 8(1):17812. PubMed ID: 30546030
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic neuroendocrine tumor associated with humoral hypercalcemia of malignancy and carcinoid tumor: a case report and review of the literature.
Shah RH; Martinez D
Pancreas; 2013 Apr; 42(3):549-51. PubMed ID: 23211368
[No Abstract] [Full Text] [Related]
15. Undifferentiated pancreatic cancer associated with humoral hypercalcemia of malignancy.
Kakizaki S; Ohya N; Yoshinaga T; Higuchi T; Kitazawa R; Takayama H; Takagi H; Nagamine T; Mori M
Jpn J Clin Oncol; 1998 Sep; 28(9):563-6. PubMed ID: 9793031
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review.
Srirajaskanthan R; McStay M; Toumpanakis C; Meyer T; Caplin ME
Neuroendocrinology; 2009; 89(1):48-55. PubMed ID: 18679021
[TBL] [Abstract][Full Text] [Related]
17. Reversal of Severe and Refractory Humoral Hypercalcemia With 177Lu-Octreotate Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor of the Pancreas.
Iliuta IA; Beauregard JM; Couture F; Douville P; Mac-Way F
Clin Nucl Med; 2015 Sep; 40(9):e448-50. PubMed ID: 26053724
[TBL] [Abstract][Full Text] [Related]
18. PTHrP-Induced Refractory Malignant Hypercalcemia in a Patient With Chronic Lymphocytic Leukemia Responding to Denosumab.
Salahudeen AA; Gupta A; Jones JC; Cowan RW; Vusirikala M; Kwong C; Naina HV
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):e137-40. PubMed ID: 26187654
[No Abstract] [Full Text] [Related]
19. PD-L1 expression in neuroendocrine tumors of the lung.
Tsuruoka K; Horinouchi H; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Asakura K; Nakagawa K; Sakurai H; Watanabe SI; Tsuta K; Ohe Y
Lung Cancer; 2017 Jun; 108():115-120. PubMed ID: 28625622
[TBL] [Abstract][Full Text] [Related]
20. Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour.
Teng J; Abell S; Hicks RJ; Hofman MS; Sachithanandan N; McKelvie P; MacIsaac RJ
Clin Endocrinol (Oxf); 2014 Dec; 81(6):940-2. PubMed ID: 24890549
[No Abstract] [Full Text] [Related]
[Next] [New Search]
